Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
- PMID: 28125758
- PMCID: PMC5350060
- DOI: 10.1001/jama.2017.0029
Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Comment in
-
Hemoglobin A1c as a Surrogate for Clinical Outcomes in Diabetes Studies.JAMA. 2017 Jul 11;318(2):200. doi: 10.1001/jama.2017.7222. JAMA. 2017. PMID: 28697248 No abstract available.
References
-
- Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. - PubMed
-
- Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–242. - PubMed
-
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
